Seelos Therapeutics, Inc. (SEEL)
After hours:
| Previous Close | 3.0000 |
| Open | 3.0400 |
| Bid | 3.4400 x 500 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.7701 - 3.8300 |
| 52 Week Range | 2.7700 - 844.8000 |
| Volume | |
| Avg. Volume | 535,237 |
| Market Cap | 1.981M |
| Beta (5Y Monthly) | 1.85 |
| PE Ratio (TTM) | 0.01 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Associated Press Finance
Seelos: Q2 Earnings Snapshot
NEW YORK (AP) — Seelos Therapeutics, Inc. SEEL) on Wednesday reported earnings of $1.7 million in its second quarter. The New York-based company said it had profit of 12 cents per share.
- Reuters
UPDATE 2-Seelos Therapeutics' ALS treatment fails mid-stage study
Seelos Therapeutics' experimental ALS drug did not meet the main goal of a mid-stage trial, the company said on Tuesday, the latest study setback in a field littered with clinical failures. The drug, SLS-005, when tested in 120 patients, failed to show statistically significant improvement in motor function and reducing mortality in patients with ALS, or amyotrophic lateral sclerosis, versus a placebo. ALS affects 16,000 to 32,000 people in the United States, and has long eluded researchers searching for an effective treatment.
- Insider Monkey
11 Best Psychedelic Stocks to Buy in 2024
In this article, we discuss 11 of the best psychedelic stocks to buy in 2024. If you want to see more stocks in this selection, check out 5 Best Psychedelic Stocks to Buy. Unlike substances like marijuana or cocaine, psychedelics are potent and serve as a form of gateway to an ‘alternate reality’ for those […]
